OpenAI pushes for bigger role in life sciences

OpenAI called for broader use of AI in life sciences in a new report, saying better access to medical data and more spending on compute, labs, energy, and other infrastructure could speed drug discovery.

The company said AI can help researchers connect fragmented knowledge, design new tools, and shorten some experiments from months to days, and cited one analysis that estimated clinical phase timelines could fall by more than 20%.

OpenAI also said GPT-5 Pro could help find new uses for FDA-approved drugs, but only a small number of AI-discovered or AI-designed drugs have reached clinical trials.

No fully AI-discovered or AI-designed drug has cleared phase 3 trials, and a mid-2025 Nature Medicine paper found AI-discovered drugs had phase 2 failure rates similar to other drugs.

🔗 Source: Axios

🧠 Food for thought

Implications, context, and why it matters.

Pharma giants are already betting on AI beyond just drug discovery

Several large pharmaceutical companies are already pursuing similar plans through partnerships 1.
Novo Nordisk’s collaboration with OpenAI aims to weave AI into research and development across the company 1. The plan covers manufacturing, supply chain operations, and corporate functions worldwide 1.
Eli Lilly signed a deal with OpenAI in 2024 to find new medicines for drug-resistant bacteria 1.
Workforce training sits at the center of the agreement 2. Novo Nordisk expects OpenAI to raise AI literacy across its global staff so employees can use the tools in daily work 2.

AI’s near-term impact in pharma may be operational, not yet scientific

Near-term payoff may come from streamlining business tasks and research workflows, rather than from brand-new drugs 3.
End-to-end AI drug development remains far off 3. AI already speeds work such as clinical trial design and patient enrollment 3.
Novo Nordisk pairs Nvidia partnerships with OpenAI tools to cover different timelines 3, 1. Nvidia, the chip designer known for AI computing systems, supports long-horizon discovery on supercomputers 3. OpenAI’s products target faster operational improvements 1.